Figure 7. Addition of PD-L1 mAb to CTLA-4 mAb did not enhance MOC1 tumor control or rejection rates.

Mice bearing established MOC1 tumors were treated with PD-L1 mAb (clone 10F.9G2, 200 μg/injection) alone or in combination with CTLA-4 mAb (clone 9H10, 100 μg/injection) and followed for tumor growth and survival. Treatment schema, individual tumor growth curves and survival are shown. *, p < 0.05; ***, p < 0.001.